Home
|
Contact
|
Pharmacovigilance
|
Medical Information
|
ITA
ENG
Welcome to
Chiesi group
Enter at least 3 characters
About us
History
Mission and Values
Governance
Benefit Corporation and B Corp
Annual and Sustainability Report
Chiesi in the world
Main areas
Research and Development
Pipeline
Clinical Trial Transparency and Data Sharing
Chiesi Clinical Studies
Manufacturing plants
Partnering
Why Chiesi as a partner
Therapeutic Focus
Who we are
Where we are
Events
Open Innovation - The Impulse
Digital Health
Working at Chiesi
Sustainability
Our approach
Ethics and Transparency
Patients at the Center
Environment
Global Value Chain
Chiesi people
Communities
Media area
News
Press Release
Contact
Home
>
Press release
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership...
Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene editing...
Chiesi Completes Clinical Development Program for Carbon-Minimal Pressurized...
Chiesi Group accelerates sustainable growth in H1 2025, delivering strong...
ARCHIVE PRESS RELEASE
Chiesi Foundation’s NEST Partners Meeting in Sub-Saharan Africa
27 Ottobre 2023
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
01 Settembre 2023
Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health to Overall Well-Being, New Report Warns
07 Settembre 2023
Chiesi Group mid-year financial results demonstrate strong growth for 2023
03 Agosto 2023
Chiesi's Sustainability Report 2022: a year of tangible achievements for patients, communities, and the planet
27 Luglio 2023
Alessandro Chiesi appointed Chair of the Chiesi Group
Maria Paola Chiesi becomes the Vice Chair
07 Luglio 2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23 Giugno 2023
Chiesi Global Rare Diseases Announces FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
10 Maggio 2023
Chiesi Global Rare Diseases Announces European Commission (EC) Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05 Maggio 2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12 Aprile 2023
<<
1
2
3
4
5
6
7
8
9
CHIESI ON THE WEB
Australia
Chiesi Australia
Austria
Chiesi Pharmaceuticals GmbH
Belgium
Chiesi SA/NV
Brazil
Chiesi Farmacêutica Ltda
Bulgaria
Chiesi Bulgaria EOOD
Canada
Chiesi Canada Corp
China
Chiesi Pharmaceutical (Shanghai) Co., Ltd
Czech Republic
Chiesi CZ s.r.o.
Denmark
Chiesi Pharma AB
Finland
Chiesi Pharma AB
France
Chiesi SAS
Germany
Chiesi GmbH
Greece
Chiesi Hellas Α.Ε.Β.Ε.
Hungary
Chiesi Hungary Kft.
Italy
CHIESI Italia S.p.A.
Japan
Chiesi Pharma Japan K.K.
Mexico
CHIESI MÉXICO
Norway
Chiesi Pharma AB
Pakistan
CHIESI PAKISTAN
Poland
Chiesi Poland
Romania
Chiesi România S.r.l.
Russia
Chiesi Pharmaceuticals LLC
Slovak Republic
Chiesi Slovakia s.r.o
Slovenia
Chiesi Slovenija, d.o.o
Spain
CHIESI ESPAÑA S.A.U
Sweden
Chiesi Pharma AB
The Netherlands
Chiesi Pharmaceuticals B.V.
Turkey
Chiesi İlaç Ticaret A.Ş
United Kingdom
Chiesi Limited
United States
Chiesi Usa, Inc.
